Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Lancet Respir Med. 2020 Jan 13;8(3):247–257. doi: 10.1016/S2213-2600(19)30369-8

Figure 3. Kaplan-Meier survival curve in HARP-2 stratified by phenotypes assigned using a 3-variable ancillary parsimonious model (interleukin-6, soluble tumour necrosis factor receptor-1, and vasopressor-use) and treatment (simvastatin or placebo).

Figure 3

Class was assigned using a probability cut-off of ≥ 0·5 to assign phenotype. The number of patients censored at the analysis end-point for each phenotype and treatment level are presented in brackets. A. Censored at 28 days; B. Censored at 90 days.